The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 119 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] 35. Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, Shapiro MS, Shenkman L 2002 Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese. Obes Res 10:1217-1221 sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] 75. Smith RE, Maguire JA, Stein-Oakley AN, Sasano H, Takahashi K, Fuku- shima K, Krozowski ZS 1996 Localization of 11-hydroxysteroid dehydro- genase type II in human epithelial tissues. J Clin Endocrinol Metab 81:3244 - 3248 source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] 51. Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cav- agnini F 2007 Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab 92:4123- 4129 source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] 30. Batista DL, Riar J, Keil M, Stratakis CA 2007 Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics 120: e575-e586 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Items 2,401–2,500 of 2,716
Causes rares et tumorales d'hyperandrogénie
Catteau-Jonard, S., Ambassa, N., Proust-Richard, C., et al. (2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75965-9.00014-3
Pituitary Surgery for Cushing Disease
Jones, P. S., & Swearingen, B. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64312-x
White, P. C. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0755-7.00571-6
McMahon, G. T. (2014) · Oxford University Press eBooks · doi:10.1093/med/9780199358274.003.0056
Endocrine and Metabolic Symptoms of Cancer and Its Treatment
Dev, R. (2018) · Springer eBooks · doi:10.1007/978-3-319-90990-5_15
Störungen der Nebennierenfunktion bei Kindern und Jugendlichen
Partsch, C., & Riepe, F. G. (2020) · Springer Reference Medizin · doi:10.1007/978-3-642-54671-6_90-2
Dasgupta, A., & Wahed, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-815960-6.00003-0
Nockel, P. J., Lakis, M. E., & Kebebew, E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64279-4
Rayfield, E. J. (2010) · Insulin · doi:10.1016/s1557-0843(10)80004-1
Utz, A. L., & Klibanski, A. (2009) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000300022.92414.34 · Cited by 1
“If the corticotropin source is outside the pituitary, a significant gradient will not be present (Nieman et al, 2008).”
BackgroundFlitsch, J., Taylor, D. G., & Jane, J. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-04152-6_12
Halperin, F., & Kaiser, U. B. (2014) · doi:10.1093/med/9780199358274.003.0046
14. Update on Diagnosis and Treatment of Endocrine Hypertension.
Hirata, Y. (2010) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.99.2314
Nebennierenüberfunktion bei Kindern und Jugendlichen
Kamrath, C., & Riepe, F. G. (2018) · Springer Reference Medizin · doi:10.1007/978-3-662-52794-8_35-1
Bourdeau, I., & Forget, H. (2010) · Springer eBooks · doi:10.1007/978-0-387-79948-3_548
Adrenocortical Carcinoma: Diagnosis and Therapy
Terzolo, M., Puglisi, S., Perotti, P., Claps, M., Roca, E., & Berruti, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65243-1
(2012) · Elsevier eBooks · doi:10.1016/b978-3-437-41797-9.16001-7
Feocromocitomi ACTH secernenti
Voltan, G., Pinelli, S., Scaroni, C. M., & Ceccato, F. (2022) · L Endocrinologo · doi:10.1007/s40619-022-01067-8
“000 abitanti/anno) causata da una secrezione autonoma e sregolata di cortisolo [3].”
BackgroundObesity secondary to endocrinology syndrome in a polymorbid patient
Mañas-Martínez, A. B., Morillo-Vanegas, D., Cameo, R. B., & Marcos-Mondón, S. (2022) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2022.02.006
The Demonstration of Tumor Heterogeneity using 2DE Proteomic Approach
Kanlı, A., Şimşek, T., Kasap, M., Akpınar, G., & Cantürk, Z. (2022) · Sakarya Medical Journal · doi:10.31832/smj.1066524
Jackson, K., Simons, Z., & Moseley, K. F. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108942751.031
Diagnostic Evaluation of Pediatric Hypertension
Larkins, N., & Roebuck, D. J. (2022) · Springer eBooks · doi:10.1007/978-3-319-31420-4_32-2
Challenges in Diagnosis and Management of Cushing's Disease
Bondugulapati, L. N. R., & Lansdown, A. (2022) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0042-1748863 · Cited by 1
Approccio diagnostico al paziente con sospetta ipertensione endocrina
Firmani, F., & Giacchetti, G. (2022) · L Endocrinologo · doi:10.1007/s40619-022-01092-7
27-year-old man • muscle weakness • fatigue • electrolyte abnormalities • Dx?
Squibb, A. (2022) · The Journal of Family Practice · doi:10.12788/jfp.0455
Exploration biochimique de la corticosurrénale
Pilon, A., & Laudat, A. (2022) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(22)00246-5 · Cited by 1
Мислення Як Фактор Самотворення Людини: Ситуація Антропоезису
Володимирівна, І. Н. (2016) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.208936
Management of the Patient with Cushing’s Syndrome During Pregnancy
Valassi, E., Martel‐Duguech, L., & Webb, S. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-99918-6_16
Obesidad secundaria a síndrome endocrinológico en paciente pluripatológica
Mañas-Martínez, A. B., Morillo-Vanegas, D., Cameo, R. B., & Marcos-Mondón, S. (2022) · Revista Clínica Española · doi:10.1016/j.rce.2022.02.009
Antonić, T., Petrović-Mucok, A., & Stefanović, A. (2022) · Arhiv za farmaciju · doi:10.5937/arhfarm72-36043
Coexistence of Bone and Vascular Disturbances in Patients with Endogenous Glucocorticoid ExcessPreprint
Yano, C., Yokomoto‐Umakoshi, M., Fujita, M., Umakoshi, H., Iwahashi, N., Katsuhara, S., Kaneko, H., Ogata, M., Fukumoto, T., Trada, E., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4089144
Cushing’s Disease: Preconception Management
Nieman, L. K. (2022) · Springer eBooks · doi:10.1007/978-3-030-99918-6_10
Self-citationAlexandre, M. I., Garrido, P., & Marques, P. (2022) · Acta Médica Portuguesa · doi:10.20344/amp.18689
Actualidades en el síndrome de Nelson
Blanco-Soborio, A., Terrones-Lozano, A., Montiel-Castillo, H., Acero, I. M., Zacate-Rojas, J. C., Velázquez-Ledesma, K. P., & Ortiz-Reyes, R. A. (2022) · Revista Mexicana de Endocrinología Metabolismo y Nutrición · doi:10.24875/rme.21000021
Il rischio cardiovascolare nel paziente con lesione surrenalica
Tucci, L., & Dalmazi, G. D. (2022) · L Endocrinologo · doi:10.1007/s40619-022-01148-8
“A causa delle numerose complicanze sistemiche, il tasso di mortalità della sindrome di Cushing non trattata è di circa 5 volte quello della popolazione generale e le malattie cardiovascolari sono una causa comune di mortalità in questi pazienti [6].”
BackgroundSíndrome de Cushing secundario a adenoma adrenocortical ectópico
Merino-Viveros, M., de Paz, I. P., de Armas, G. G., et al. (2017) · Revista Española de Casos Clínicos en Medicina Interna · doi:10.32818/reccmi.a2n2a2
Wexler, T., & Page‐Wilson, G. (2022) · doi:10.22541/au.166746244.47678512/v1
Possibili errori nella diagnostica della Sindrome di Cushing
Mondin, A., Ceccato, F., Scaroni, C. M., & Voltan, G. (2022) · L Endocrinologo · doi:10.1007/s40619-022-01183-5
“Le linee guida della Endocrine Society suggeriscono l’utilizzo di tre test di primo livello per la dimostrazione dell’eccesso di cortisolo: 1) cortisolo libero urinario (Urinary Free Cortisol, UFC); 2) cortisolo salivare serale (Late Night Salivary Cortisol, LNSC); e 3) test di soppressione con desametasone a basse do…”
BackgroundBruising, hair loss, and stretch marks in a 23-year-old woman
Peters, S. M. (2022) · JAAPA · doi:10.1097/01.jaa.0000892716.61492.65
(2022) · American Registry of PathologyArlington, Virginia eBooks · doi:10.55418/9781933477251-4
Thiolliere, D., Harbaoui, B., Falandry, C., et al. (2022) · PubMed · doi:10.11909/j.issn.1671-5411.2022.11.005
Pereira, A. M., & Dekkers, O. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99899-4.00006-8
Balaustren, V., Jaspe, J., Aure, G., & Camperos, P. (2022) · Revista Científica CMDLT · doi:10.55361/cmdlt.v15i2.124
“2021; 15(2): e-201124 Enfermedad de Cushing: análisis de morbimortalidad asociada en pacientes del Centro Médico Docente la Trinidad.”
BackgroundInfluentialNon-A–non-B dissection with Cushing's syndrome
Chen, B., Wang, Z., Zhang, R., Liu, H., Chen, Y., & Wei, M. (2022) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2022.12.083
Arega, G., Hailu, D., Mohammed, A., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2366302/v1
Khalil, S. S., Sheikh‐Ahmad, M., Sarah-Hefer, T., Yovanovich, E., Reut, M., Chen‐Konak, L., Khazen, N. S., & Saiegh, L. (2023) · Endocrine Research · doi:10.1080/07435800.2023.2176869
“This sensitivity is higher than those commonly reported (95–98%).(2) As our center is a tertiary one, patients with suspected CS but normal ODST or MSC probably were not referred to us for further evaluation, and this may explain the 100% sensitivity we observed.”
ResultStifel, U., Vogel, F., Caratti, G., Reincke, M., & Tuckermann, J. P. (2023) · medRxiv · doi:10.1101/2023.02.28.23286599
Chu, W.-K., Wang, C., Wu, W.-C., & Wu, V. (2023) · Research Square · doi:10.21203/rs.3.rs-2658889/v1
Screening per la Sindrome di Cushing: vecchi consigli che restano attuali
Mondin, A., Boscaro, M., & Scaroni, C. M. (2023) · L Endocrinologo · doi:10.1007/s40619-023-01249-y
Hydrosaline Alterations in Cushing Disease
Alcubierre, D. D., Sbardella, E., & Isidori, A. M. (2023) · Endocrinology · doi:10.1007/978-3-030-44628-4_15-1
Endocrine Hypertension: Overview of Current Understanding
Chowdhury, C., Aman, R., Siddiqua, A., Mamiun, M. A. A., Rohan, M. I., Hasan, M. M., Rafeya, I., Zaman, M., Amiruzzaman, M., Haque, F., et al. (2023) · Cardiovascular Journal · doi:10.3329/cardio.v15i2.65631
Cushing’s Disease in Pregnancy and Cabergoline Use: Obstetric and Neonatal Outcomes
Murillo, N. B., Ramacciotti, C. F., Otta, C. F., & Cecenarro, L. A. (2023) · Advances in Obstetrics and Gynecology Research · doi:10.26689/aogr.v1i1.4947
“34 Volume 1; Issue 1 the second and third trimester, UFC also increases; therefore, UFC should not be considered a reliable marker after the first trimester, unless the increase is 2 to 3 times with respect to the NV ([9]).”
BackgroundZhang, C., He-lian, M., Qu, H., Du, H., Liu, Z., Chen, J., Huang, Q., Guo, L., Nie, B., & Liu, M. (2023) · American Journal of Hypertension · doi:10.1093/ajh/hpad053
Trandafir, A.-I., Stanciu, M., Albu, S. E., Stoian, V. R., CIOFU, I., Persu, C., Nistor, C., & Carşote, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134244 · Cited by 2
“Today, the shift from using the term “SCS” to “ACS” has occurred in daily practice; the key assay remains the serum cortisol level after 1-mg DST [16,17,87,88].”
BackgroundARMC5-negative primary bilateral macronodular adrenal hyperplasia
Sol, B., Carprieaux, M., & Leu, N. D. (2023) · BMJ Case Reports · doi:10.1136/bcr-2022-254099
A 72-Year-Old Woman with Fatigue and Shortness of Breath
Hansrivijit, P., Thurber, E. G., Malkani, N. P., Chen, W. Y., Goldsmith, J. D., Kaiser, U. B., & Gupta, S. (2023) · NEJM Evidence · doi:10.1056/evidmr2300084
Ashraf, S., Parveen, S., Ashraf, S., Batool, U., Sultana, M., Ishaque, U., Shafqat, Z., Shabbir, S., Riaz, Z., & Faiz, Z. (2023) · BioScientific Review · doi:10.32350/bsr.52.04
“It is characterized by low specificity but great sensitivity [24].”
BackgroundHonour, J. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818124-9.00019-x
Pituitary, adrenal and thyroid dysfunction
Fernandes, T., Rollo, J., & Llano, A. (2023) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2023.07.002
Disorders of the adrenal gland
Strother, M. C., & Kutikov, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-77575-5.00032-0
COEXISTENCE OF PHEOCHROMOCYTOMA AND HYPERCORTISOLEMIA. DIAGNOSTIC DIFFICULTIES
Krzemińska, M., & Kruzel-Piszczek, A. (2023) · Polski Merkuriusz Lekarski · doi:10.36740/merkur202304118
Cushing Syndrome Caused by Pituitary and Adrenal Hybrid Tumor: A Rare Case Report
Dave, M., Doshi, A., Mangla, N., et al. (2023) · Indian Journal Of Clinical Practice · doi:10.59793/ijcp.v34i5.676
La malattia di Cushing in età pediatrica: epidemiologia, diagnosi e approcci terapeutici
Ferrigno, R., Cioffi, D., Pellino, V., Savanelli, M. C., & Klain, A. (2023) · L Endocrinologo · doi:10.1007/s40619-023-01383-7
Masrour, M. (2023) · Springer eBooks · doi:10.1007/978-3-319-66816-1_1822-1
Does Desmopressin Impact Lateralization in Bilateral Inferior Petrosal Sinus Sampling?Preprint
Erkan, B., Cil, M. S., Cingöz, M., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3666933/v1
Low Urinary Free Cortisol as a Risk Factor for Patients with Variceal Bleeding
Aggeletopoulou, I., Tsounis, E. P., Kalafateli, M., Michailidou, M., Tsami, M., Zisimopoulos, K., Mandellou, M., Διαμαντοπούλου, Γ., Kouskoura, M. G., Michalaki, M. A., et al. (2023) · Medicina · doi:10.3390/medicina59122112
“Moreover, 24h UFC has been characterized as a dependable indicator for diagnosing hy-percortisolism [61].”
BackgroundCorrales, E. P., Cancela, A. A., Baonza, G., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3714302/v1
Diagnoselabyrinth: Morbus Cushing
Manstein, M., Piel, E., Stümvoll, M., & Kische, S. (2024) · Die Innere Medizin · doi:10.1007/s00108-023-01653-4
Diabetes in Hypersecreting Endocrine Disorders
Vaag, A. A., Hanley, N. A., & Kistorp, C. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch22
Prednisolone-Induced Cushing's syndrome: A case report
Geetha, K., Sahithya, U. L., Smaigdhini, C., et al. (2024) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2024.21.1.0056
“These symptoms collectively signal the need for medical assessment and tailored management strategies [3],[4] .”
BackgroundHypercortisolaemia without clinical stigmata of Cushing syndrome
Krishna, S., & Morton, A. (2024) · BMJ Case Reports · doi:10.1136/bcr-2023-258286
Endocrine Disorders Associated with Obesity
Park, H. K., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_42
Hypertension and severe hyperreninemia in a young man
Leisring, J. M., Lyou, J., Obole, E. L., et al. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.23055
Krzentowska, A., Gołkowski, F., & Czepko, R. A. (2023) · The Journal of Neurological and Neurosurgical Nursing · doi:10.15225/pnn.2023.12.3.5
Bučinskaitė, E., & Kaupas, R. S. (2024) · Health Sciences · doi:10.35988/sm-hs.2024.024
Subcentimeter Corticotroph Adenoma: an Evaluation of Diagnostic Elements
Lai, Y. Y., Thambiah, S. C., Mokhtar, N., & Samsudin, I. N. (2023) · Malaysian Journal of Medicine and Health Sciences · doi:10.47836/mjmhs.19.s16.10
Improving the radiological prediction of surgical resection of nonfunctioning pituitary adenomasPreprint
Giardini, E., Barbosa, M. Á., Ventura, N., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3938315/v1
Adrenal Multidisipliner Güncel Yaklaşım
Özen, F. Z., Özer, M., Özsoy, Ç., Binnetoğlu, E., Alparslan, A. Ş., Budak, E. S., Kök, E. V., Çetinkaya, G. S., Durmuş, M. E., Köker, G., et al. (2024) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.2992
Delayed Diagnosis of Ectopic Cushing Syndrome
Matson, B. C., Evron, J. M., Johnson, S. M., Zeitler, E. M., & Klein, K. R. (2024) · JCEM Case Reports · doi:10.1210/jcemcr/luae034
“We suspect that in most such situations, a random serum cortisol measurement is far more likely to be ordered than a validated screening test, such as dexamethasone suppression testing, urine free cortisol, and late-night salivary cortisol per Endocrine Society guidelines (5).”
BackgroundInfluentialWang, B., Yang, Y., Yuan, H., et al. (2024) · doi:10.22541/au.170666548.85695277/v1
Bertog, S. C., Vaškelytė, L., Drexel, T., Hofmann, I., Id, D., Gafoor, S. A., Reinartz, M., & Sievert, H. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-26219-4.00022-0
Patil, P., Monteiro, J., Qureshi, S. S., & Karnik, N. (2024) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0044-1780522
Unveiling the Uncommon: Cushing’s Syndrome (CS) Masquerading as Severe Hypokalemia
Khan, W., Kazman, M., Abeer, H., et al. (2024) · Cureus · doi:10.7759/cureus.58695
Das Nebennierenrindenkarzinom: Ein seltener Tumor mit anspruchsvoller Therapie
Filmar, S. (2024) · Uro-News · doi:10.1007/s00092-024-6299-9
Brosolo, G., Porto, A. D., Bulfone, L., Vacca, A., Bertin, N., Vivarelli, C., Catena, C., & Sechi, L. A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1397062
Adrenal insufficiency (hypocorticism) on the background of adrenalectomy for corticosteroma
Titova, V. V., Demidova, T. Y., Muslimova, K. M., & Быков, А. В. (2023) · Endocrine Surgery · doi:10.14341/serg12798
A Rare Cyclic Cushing Syndrome Mystery Illustrates Diagnostic Principles
Omotosho, Y. B., McGlotten, R., Pacák, K., Wierman, M. E., & Nieman, L. K. (2024) · JCEM Case Reports · doi:10.1210/jcemcr/luae094
Self-citationSteroid Profiling in the Differential Diagnosis of Cushing's Syndrome and Diagnosis of MACS
Nankova, A., Kamenova, T., Vasilev, V., Elenkova, A., Svinarov, D. A., Кirilov, G., & Zaharieva, S. (2024) · Acta Medica Bulgarica · doi:10.2478/amb-2024-0012
Hipercortisolismo de origen adrenal
Corrales, E. P., Castro, M. A., Ortiz-Flores, A. E., & Escobar-Morreale, H. F. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.06.010
Incidentaloma suprarrenal. Abordaje diagnóstico y de tratamiento a propósito de un caso
Castro, M. A., Corrales, E. P., Ortiz-Flores, A. E., & Escobar-Morreale, H. F. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.06.018
Indicaciones e interpretación de los estudios analíticos hormonales de la corteza suprarrenal
Castro, M. A., Corrales, E. P., Ortiz-Flores, A. E., et al. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.06.015
From Nelson’s Syndrome to Corticotroph Tumor Progression Speed: An Update
Bessiène, L., Villa, C., BERTAGNA, X. Y., Baussart, B., & Assié, G. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2359-8649
“In Cushing’s disease, the regulation of ACTH is partially resistant to negative glucocorticoid feedback [72].”
Mondin, A., Ceccato, F., Scaroni, C. M., & Barbot, M. (2024) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303328077240719055819
A Validated Method for the Simultaneous Determination of Oxytocin and Cortisol in Human Saliva
Polledri, E., Mercadante, R., Campo, L., & Fustinoni, S. (2024) · Separations · doi:10.3390/separations11080240 · Cited by 1
“Currently, the determination of CORT levels is proposed in clinical practice to aid the diagnosis of altered hypothalamic–pituitary–adrenal axis secretion, which occurs in cases of Cushing’s syndrome or subclinical hypercortisolism [7].”
BackgroundTrandafir, A.-I., Stanciu, M., Valea, A., Sima, O.-C., Nistor, C., Iliescu, M. G., Ciobanu, I., Popa, F. L., & Carşote, M. (2024) · Balneo and PRM Research Journal · doi:10.12680/balneo.2024.692
Cushing’s Syndrome Masquerading as Fibromyalgia: A Case Series
Samsam, H. H. A., Fazal, F., Nokhatha, S. A. A., Aljaberi, A. K., Adam, A., Huwaijah, S. H., & Bekhit, W. (2024) · Cureus · doi:10.7759/cureus.68181
“According to the 2008 Endocrine Society guidelines, Cushing syndrome’s diagnosis is made by lab tests that show consistently high production of cortisol using 24-hour urine free cortisol level, low-dose (1mg) dexamethasone suppression test, or late-night salivary or serum cortisol [5].”
MethodCase 3: Psychiatric Distress, Hypertension, and Weight Gain in an Adolescent Male
Hicks, K., Graf, J. M., Zafar, S., & Waguespack, S. G. (2024) · Pediatrics in Review · doi:10.1542/pir.2023-005960
Endocrine and Metabolic Dysfunction and Oro‐Facial Diseases
Chirravur, P., & Chirravur, P. (2024) · Wiley eBooks · doi:10.1002/9781119989233.ch9 · Cited by 2
Encefalopatie metaboliche e tossiche
Bureau, J., Codron, P., & Verny, C. (2024) · EMC - Neurologia · doi:10.1016/s1634-7072(24)49602-5
Ragnarsson, Ó., & Falhammar, H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00114-x
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.